Physician profile
Gary L Chan
NPI 1699702324
$1,809.65
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $139 · 2021: $125 · 2024: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $315.02 | 2019-2020 | |
| Amgen INC. | $264.91 | 2020-2024 | Tavneos |
| Viiv Healthcare Company | $226.98 | 2019-2020 | |
| Gilead Sciences, INC. | $216.27 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $205.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $87.84 | 2019 | |
| Abbvie INC. | $71.36 | 2019 | |
| Lilly USA, LLC | $57.13 | 2019 | |
| Merck Sharp & Dohme LLC | $52.51 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $52.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.37 | 2019-2020 | |
| Novo Nordisk INC | $34.96 | 2019 | |
| Glaxosmithkline, LLC. | $31.18 | 2019 | |
| Janssen Biotech, INC. | $30.08 | 2019 | |
| Pfizer INC. | $30.08 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $29.86 | 2019 | |
| Astellas Pharma US INC | $23.67 | 2019 | |
| Vyera Pharmaceuticals, LLC | $16.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.57 | 2019 | |
| Biodelivery Sciences International, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.